Analyst Price Targets — SABS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 24, 2026 11:23 am | Eliana Merle | Barclays | $13.00 | $3.87 | TheFly | SAB Biotherapeutics initiated with an Overweight at Barclays |
| May 20, 2026 9:00 am | — | Jefferies | $11.00 | $3.55 | TheFly | SAB Biotherapeutics initiated with a Buy at Jefferies |
| May 12, 2026 3:58 pm | Emily Bodnar | H.C. Wainwright | $10.00 | $3.65 | TheFly | SAB Biotherapeutics price target raised to $10 from $7 at H.C. Wainwright |
| January 7, 2026 6:01 am | Michael Yee | UBS | $7.00 | $3.62 | StreetInsider | UBS Starts SAB Biotherapeutics (SABS) at Buy |
| September 17, 2025 10:58 am | — | Leerink Partners | $7.00 | $2.58 | TheFly | SAB Biotherapeutics initiated with an Outperform at Leerink |
| June 7, 2024 3:45 am | Kumaraguru Raja | Loop Capital Markets | $8.00 | $2.84 | StreetInsider | Brookline Capital Markets Starts SAB Biotherapeutics (SABS) at Buy |
| April 2, 2024 6:44 am | Edward White | H.C. Wainwright | $6.00 | $4.29 | StreetInsider | SAB Biotherapeutics (SABS) PT Lowered to $6 at H.C. Wainwright following Q4 report |
| August 11, 2022 7:41 am | — | Chardan Capital | $3.00 | $1.12 | Benzinga | Chardan Capital Maintains Buy on SAB Biotherapeutics, Lowers Price Target to $3 |
Latest News for SABS
Shares of SAB Biotherapeutics, Inc. (NASDAQ: SABS - Get Free Report) have earned a consensus rating of "Moderate Buy" from the eleven research firms that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and nine have assigned a buy recommendation to
MIAMI, July 07, 2026 (GLOBE NEWSWIRE) -- Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization and SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for T1D and other autoimmune diseases, today announced that Breakthrough T1D has awarded a grant to Michael J. Haller, M.D.,…
Data will highlight deeper mechanistic insights and long-term dosing potential of SAB-142, a fully human multi-specific ATG for newly diagnosed Stage 3 T1D Data will highlight deeper mechanistic insights and long-term dosing potential of SAB-142, a fully human multi-specific ATG for newly diagnosed Stage 3 T1D
SAB Biotherapeutics NASDAQ: SABS said its lead type 1 diabetes candidate, SAB-142, remains on track in a registrational Phase 2b trial, as the clinical-stage biopharmaceutical company reported a wider first-quarter loss alongside higher research and development spending.
Continued site activation in registrational SAFEGUARD trial of SAB-142; enrollment ongoing and on track to be completed by end of 2026 with topline data expected in 2H 2027
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for SABS.
U.S. House Trading
No House trades found for SABS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.